NanoViricides, Inc. Reports That NNVC is in the Preliminary Additions List of The Russell Global, The Russell 3000, The Russe...
June 16 2014 - 7:00AM
Business Wire
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"), reports
that NanoViricides, Inc. is in the preliminary list for addition to
the Russell Global, Russell 3000, Russell 2000, and Russell
Microcap Indexes when Russell Investments (“Russell”) reconstitutes
its U.S. and global equity indexes on June 27, 2014. The
preliminary additions and deletions for the Russell Global, Russell
3000® and Russell Microcap® Indexes were listed on the Russell
website on Friday, June 13, 2014, after the U.S. stock market
closed
(http://www.russell.com/indexes/americas/tools-resources/reconstitution/additions-deletions.page).
Russell will provide further updates on Friday, June 20 and 27. The
newly reconstituted Russell indexes will take effect after the US
stock market close on Friday, June 27.
The most popular of these indexes is called the Russell 2000, a
small-cap index, in existence for over 30 years. According to the
Russell website, it “has been widely adopted by both institutional
and retail investors for measuring performance of the small cap
U.S. equity market, due to its accurate, comprehensive
methodology”. The Russell 2000 is a part of the Russell 3000 that
additionally includes the Russell 1000 companies. The latter is an
index of the 1000 largest publicly-traded companies. More
information about the Russell family of indexes can be found at
http://www.russell.com.
The Company believes that this addition to Russell indexes is
very significant in that it will give NanoViricides much greater
visibility in the financial community. The Company has been
informed that JPMorgan and Deutsche Bank investment banks have
recently published reports that state an estimated total of
3,378,000 shares of NNVC could be purchased in the near term by
various index-based funds, if the Company is added to the Russell
indexes in their final June 2014 annual reconstitution.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for antiviral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon,
310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jul 2023 to Jul 2024